Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2012

View Archived Issues

Johnson & Johnson presents highlights of third quarter 2012

Recent clinical data support approval of canagliflozin

Gene polymorphism linked to acute lung injury in Gram-negative sepsis

Tocilizumab shows positive effects in patients with neuromyelitis optica

Novel PI3K and mTOR inhibitors patented by Pathway Therapeutics

Abbott updates pipeline progress of third quarter 2012

New gamma-secretase modulators prepared at Pfizer

Chugai presents interim phase II results for CH-5424802

Prozymex presents new DPP-I inhibitors

CHMP recommends approval of Krystexxa

New agents for bacterial infections synthesized by Actelion Pharmaceuticals

Natco Pharma prepares new salts of anticancer agent

Actelion submits macitentan NDA

Amgen patents novel pim inhibitors

A novel marker can predict the outcome in osteosarcoma

Alnylam and Genzyme form RNAi therapeutics alliance in Asia

NXT-182 prevents neuronal apoptosis in vitro and increases neurogenesis in vivo

Health Canada approves new drug submission for Cinryze

Derma Sciences to begin phase III DSC-127 program

Astellas Pharma launches Myrbetriq in U.S.

Kaken submits application in Japan for topical antifungal agent

Eisai obtains FDA approval for Fycompa

Ono and Domain Therapeutics enter GPCR collaboration

Health Canada approves Seebri Breezhaler for COPD

Ligand to receive milestone payment from Merck & Co.

Phase I trial of Kevetrin now active

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...